Blog

BY MARK SCHOLZ, MD Due to the absence of well-designed comparative studies, treatment selection for prostate cancer has been highly controversial. However, in October 2016, two landmark articles published in the New England …

BY MARK SCHOLZ, MD It seems we have a national passion for prostate biopsies. A million men are biopsied every year. Two hundred thousand of them will be diagnosed with prostate cancer …

BY MARK SCHOLZ, MD A number of interventions are available that can substantially reduce adverse side effects from testosterone inactivating pharmaceuticals (TIP).  Side effects vary from patient to patient and are influenced by the …

BY MARK SCHOLZ, MD New prostate cancer drugs come to market quite rarely because the studies mandated by the FDA cost hundreds of millions of dollars. The FDA requires these studies to randomly allocate men into …

BY MARK SCHOLZ, MD It is generally understood that diabetes is a disease of insulin deficiency. Until now, it has not been widely recognized that insulin is high-octane fuel for …

BY MARK SCHOLZ, MD One of the unique characteristics of prostate cancer is how quickly it responds to testosterone withdrawal. This “Achilles’ Heel” of prostate cancer was discovered when surgical …

BY MARK SCHOLZ, MD Google keeps track of what is searched most frequently. Since prostate cancer is common, it’s hardly surprising that people who research aches or pains “down there” …

BY MARK SCHOLZ, MD The problem now is that there is such a large number of new agents being approved in all the different types of cancer. How do you know which …

BY MARK SCHOLZ, MD A perfect test for prostate cancer should detect high-grade prostate cancer accurately while avoiding the over-diagnosis of harmless, low-grade cancers (the Gleason 6 variety). Back in 2011, the US Preventative Services …